Skip to main content

Table 2 Differences in patients who had urine drug screen testing pre vs. post commercialization in Colorado, by hospital location

From: The impact of recreational marijuana commercialization on traumatic injury

  Colorado hospitals Non-Colorado hospitals
Covariate (%) UDS performed Pre (n = 1027) UDS performed
Post (n = 1013)
P value UDS performed Pre (n = 1786) UDS performed
Post (n = 1507)
P value
Age (years), mean 42.2 43.9 0.03 41.0 39.8 0.06
Male sex 69.9% 72.2% 0.26 67.4% 69.7% 0.15
Non-White race 28.1% 24.7% 0.08 23.7% 37.0% < 0.001
Glasgow Coma score 3–8 17.2% 16.6% 0.74 17.7% 19.6% 0.16
Injury severity score, mean 12.8 12.7 0.87 11.5 11.4 0.95
SBP < 90 mmHg 5.0% 4.4% 0.53 3.5% 4.7% 0.08
Penetrating mechanism 7.2% 7.6% 0.85 8.7% 11.4% < 0.001
Cause of injury    0.36    < 0.001
Motor vehicle crash 43.9% 40.4%   48.6% 49.4%  
Fall 31.3% 33.0%   24.6% 20.6%  
Sports related 7.6% 8.8%   3.5% 2.1%  
Assault/Stab/GSW 14.8% 14.5%   11.5% 15.9%  
Other 2.4% 3.4%   11.8% 11.9%  
Full activation 44.3% 38.3% < 0.001 38.8% 45.7% < 0.001
ICU admission 53.4% 57.2% 0.08 53.6% 55.5% 0.27
Mortality 4.8% 4.7% 0.97 5.9% 5.1% 0.34
  1. Pre-commercialization, 2012–2013. Post-commercialization, 2014–2015. SBP systolic blood pressure, GSW gunshot wound, ICU intensive care unit. Bolding denotes p values that met the alpha < 0.05 significance level